蒽环类联合紫杉类药物新辅助化疗方案治疗乳腺癌的临床疗效

Clinical efficacy of anthracycline combined with taxine neoadjuvant chemotherapy in the treatment of breast cancer

目的探究蒽环类联合紫杉类药物新辅助化疗方案治疗乳腺癌患者的临床疗效。方法选取2020年1月至2022年12月本院收治的60例乳腺癌患者作为研究对象,按照信封法分为联合组与常规组,每组30例。常规组采用常规化疗方案,联合组采用蒽环类联合紫杉类药物新辅助化疗方案,比较两组生命质量、临床疗效及不良反应发生情况。结果化疗后,联合组生理状况、情感状况、社会/家庭状况、功能状况评分均高于常规组,差异有统计学意义(P<0.05)。联合组治疗总有效率为93.33%,明显高于常规组的73.33%,差异有统计学意义(P<0.05)。联合组不良反应发生率为6.67%,常规组为10.00%,组间比较差异无统计学意义。结论蒽环类联合紫杉类药物新辅助化疗方案治疗乳腺癌可提高患者生命质量及临床疗效,且安全性较高,值得临床推广应用。

Objective To investigate the effect of anthracycline combined with taxine neoadjuvant chemotherapy in the treatment of patients with breast cancer.Methods A total of 60 patients with breast cancer admitted to our hospital from January 2020 to December 2022 were selected as the research subjects,and they were divided into the combined group and the conventional group according to envelope method,with 30 cases in each group.The conventional group received conventional chemotherapy,and the combined group received anthracycline combined with taxine neoadjuvant chemotherapy,the quality of life,clinical efficacy and occurrence of adverse reactions were compared between the two groups.Results After chemotherapy,the physiological status,emotional status,social/family status and functional status scores in the combined group were higher than those in the conventional group,and the differences were statistically significant(P<0.05).The total effective rate of combination group was 93.33%,which was significantly higher than that of conventional group(73.33%),and the difference was statistically significant(P<0.05).The incidence of adverse reactions was 6.67%in the combined group and 10.00%in the conventional group,and there was no statistically significant difference between the two groups.Conclusion Anthracycline combined with taxine neoadjuvant chemotherapy can improve the quality of life and clinical efficacy of patients with breast cancer,and it is safe and worthy of clinical promotion and application.